HOMA-IR Insulin Resistance Calculator

A fasting glucose result of 96 mg/dL and fasting insulin of 12 µU/mL produce a HOMA1-IR estimate of 2.84. The arithmetic is straightforward; its meaning is not a green-or-red diagnosis. This HOMA-IR calculator keeps the calculation separate from the medical decision, because assay method, age, population and clinical history can all change how a clinician reads the number.

Start with the specimen, not the colour

HOMA1-IR needs fasting glucose and fasting insulin from the same blood draw. An overnight fast of at least eight hours is normally used for fasting glucose testing. Food, milk or sugar in coffee, an acute illness, hard exercise and some medicines may alter one or both measurements. Record the collection time and fasting duration before entering the values.

The glucose box accepts mg/dL. If a laboratory reports glucose in mmol/L, multiply it by 18 before using the tool. Check the insulin unit too: it must be µU/mL, a unit numerically equivalent to mIU/L for this purpose. A misplaced unit can create a plausible-looking but meaningless result.

How to calculate insulin resistance with the HOMA1 formula

The approximation used here is:

HOMA1-IR = fasting glucose in mg/dL × fasting insulin in µU/mL ÷ 405

With glucose in mmol/L, divide by 22.5 instead. For 5.3 mmol/L and 12 µU/mL, the calculation is 5.3 × 12 ÷ 22.5, which gives about 2.83. A fasting insulin calculator that uses insulin alone cannot produce this index; glucose is an essential part of the model.

HOMA1 and HOMA2 are different models

The original homeostasis model was described by Matthews and colleagues in 1985. Oxford's later HOMA2 computer model accounts for non-linear physiological responses and is not identical to the simple 405 equation. This page returns HOMA1-IR. Do not compare it directly with a laboratory result labelled HOMA2-IR or HOMA2-%S.

There is no universal HOMA-IR normal range

The value 2.5 appears frequently in articles and laboratory discussions, but it is an example research cutoff rather than an international diagnostic boundary. Published thresholds vary with study population, age, sex, puberty, pregnancy and the insulin assay used. One prospective study, for example, reported different cutoffs for women and men instead of a single number for everyone.

The result panel therefore shows where your number sits relative to 2.5 without calling the lower band healthy or the upper band a confirmed disease. A result below that point cannot exclude metabolic problems. A result above it does not establish insulin resistance on its own. If the test is being repeated, similar fasting conditions and the same laboratory make changes easier to interpret.

Prediabetes and diabetes use other diagnostic tests

People searching for an insulin resistance test often expect one decisive marker. NIDDK notes that direct testing for insulin resistance is used mainly in research. Clinical diagnosis of prediabetes and diabetes instead relies on plasma glucose, HbA1c and, when appropriate, a 75 g oral glucose tolerance test. In the absence of unequivocal hyperglycaemia, an abnormal result needs confirmation.

These values apply outside pregnancy. Anaemia, altered red-cell turnover and some haemoglobin variants can affect HbA1c, so a clinician may choose another test. HOMA-IR is not a substitute for any of them.

What is HOMA-IR useful for?

HOMA-IR is a model-based insulin resistance index. It offers a practical estimate when a research study or clinician wants to examine fasting glucose and insulin together. It is less demanding than a hyperinsulinaemic-euglycaemic clamp, the detailed reference method used in specialist research, but that convenience comes with uncertainty. The original paper reported good correlation with clamp measurements while also noting variation that limits individual interpretation.

An insulin resistance calculator can reproduce the equation and prevent arithmetic errors. It cannot know whether the sample was truly fasting, whether outside insulin was used, whether pancreatic insulin production is impaired or which cutoff is appropriate for you. HOMA may be misleading in those settings and should not determine a medicine dose.

Insulin resistance and prediabetes commonly cause no symptoms. Acanthosis nigricans, a larger waist, polycystic ovary syndrome, sleep apnoea or a family history of type 2 diabetes may accompany greater risk, but none confirms the condition. Marked thirst, frequent urination, blurred vision or unexplained weight loss calls for medical assessment of blood glucose rather than another online calculation.

Fasting insulin needs its laboratory reference

There is no single ideal fasting insulin number that applies across all laboratories. Immunoassays are not fully harmonised, so the same sample can produce different values on different systems. Read the result against the reference interval printed on that report and consider it with glucose, HbA1c, lipids, medicines and medical history.

This is also why a change from 8 to 11 µU/mL may mean less than it first appears if the tests came from different laboratories. External insulin treatment, severe reduction in pancreatic function and acute metabolic illness can further weaken the assumptions behind the model.

Bring context to the appointment

• Note the exact glucose and insulin values, units and laboratory ranges.
• Write down the fasting duration, collection time and medicines taken around the test.
• Take previous fasting glucose, HbA1c and triglyceride results if available.
• Mention pregnancy, recent illness and a family history of diabetes.

Those details help a clinician decide whether the estimate is comparable with earlier results and whether standard diabetes screening is needed.

Use the result to frame a conversation, not a treatment

Regular physical activity, a dietary pattern built around vegetables, pulses, whole grains and suitable protein sources, adequate sleep and stopping smoking can support metabolic health. For adults with overweight and high diabetes risk, the Diabetes Prevention Program found that losing about 5% to 7% of starting weight reduced progression to type 2 diabetes. That figure is not an automatic target for every person.

A clinician or registered dietitian can adapt the plan for age, muscle mass, pregnancy, eating-disorder history and other conditions. Do not start, stop or change metformin, insulin or any other medicine because of a HOMA-IR result. The useful outcome is a better-informed discussion backed by the actual laboratory report.